MPC Holds Up as Refining Peers Slide
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Marathon Petroleum is the relative winner in a week when refining stocks broadly fell, and the positioning data behind that outperformance is worth examining closely.
Among its closest peers, VLO dropped 5% on the week and PBF fell nearly 9%. PSX lost 0.6%. Against that backdrop, MPC slipped just 0.4%, a notable gap that cannot be explained by positioning alone but is consistent with a stock where short interest is genuinely thin and the borrow market is wide open. Short interest in MPC is about 2.4% of the free float, one of the lower readings in the refining group. Availability is at roughly 3,076%, meaning there are more than 30 shares available to borrow for every one already borrowed. That is not a lending market under any strain whatsoever.
Options positioning has shifted in the opposite direction from what one might expect of a stock holding up well. The put/call ratio has dropped to 1.07, roughly 2.4 standard deviations below its 20-day mean of 1.17. That is the lowest reading of the past year, which stood at 1.25 as recently as October 12. A falling PCR alongside a resilient price typically reflects a rotation away from downside hedges, consistent with investors becoming less anxious about the name specifically even as the sector sells off around it. Cost to borrow has ticked up 25% on the week to 0.45%, but from a level so low that the move is noise rather than signal.
The analyst picture has stabilised after a busy revision cycle. The previous note, published October 14, captured a wave of large target-price increases from Wells Fargo, Citigroup, and Barclays. Since then, no new changes have come through, and the consensus mean now sits at $457, modestly below the $475 close. That is a narrower discount to the stock price than this time last week, when the mean was closer to $433. Bulls point to MPLX distributions covering parent capex and dividends, refining capture above benchmark, and a balance sheet carrying parent cash near $6.7 billion against a roughly $1 billion target. The bear argument centres on crack spread cyclicality, planned renewable diesel downtime, and a 5.5x EV/EBITDA multiple that already reflects a good deal of the margin recovery. EV/EBITDA has compressed about one turn over the past 30 days, partly a function of the higher stock price absorbing some of the multiple expansion. The EPS momentum factor scores are strong, ranking in the 93rd to 94th percentile on both 30-day and 90-day windows. Analyst recommendation differential ranks in the 99th percentile, a reflection of how many firms moved targets sharply higher this month.
Wikipedia traffic to MPC's article spiked in late September, with a z-score of 2.4 against the prior 90 days. That points to a short-lived burst of retail attention rather than anything fundamental, and there are no measured leading indicators in the alt-data coverage that would sharpen the picture ahead of the Q3 print on October 27.
The earnings date is the clearest near-term reference point. After Q2 results in early August the stock fell 3% on the day before recovering to a 5-day gain of nearly 10%, so the pattern is not one of prolonged post-earnings damage. The week after the print, rather than the print itself, may be where positioning matters most. With short interest low, availability abundant, and the put/call ratio at a 12-month trough, there is little in the lending or options market that looks braced for a sharp move lower.
Stocks in this article
See the live data behind this article on ORTEX.
Open MPC on ORTEX →How this article was generated
- Generated
- 21 Oct 2026, 19:56
- Data as of
- 21 Oct 2026, 19:46
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.